Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Histamine release

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Histamine release. Displaying page 1 of 1.
    EudraCT Number: 2005-001291-12 Sponsor Protocol Number: SPON CU 085 Start Date*: 2005-04-27
    Sponsor Name:Cardiff University
    Full Title: Histamine Release and Implications of H1- and H2- Blockade in Adult Cardiac Surgery - A Randomised Controlled Study
    Medical condition: During cardiac surgery involving the use of cardiopulmonary bypass histamine is released in the blood. Histamine release has been related to an increased incidence of perioperative dysrhythmias and...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019344-39 Sponsor Protocol Number: BUCUM1 Start Date*: 2010-08-09
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Double-blind, triple cross-over, placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in cold contact urticaria (CCU) Compound:...
    Medical condition: Cold contact urticaria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002512-89 Sponsor Protocol Number: ANDA1 Start Date*: 2012-01-26
    Sponsor Name:Tayside Clinical Trials Unit, University of Dundee
    Full Title: Evaluation of any steroid sparing effect of beta blocker therapy on airway hyper-responsiveness in stable, mild to moderate, asthmatics.
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004094-93 Sponsor Protocol Number: PAFCUTIII Start Date*: 2012-04-19
    Sponsor Name:Allergie-Centrum Charité
    Full Title: Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40mg in cold contact urticaria (CCU)
    Medical condition: Cold contact urticaria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10009869 Cold urticaria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-002648-88 Sponsor Protocol Number: 3090A-101795 Start Date*: 2005-11-17
    Sponsor Name:Wyeth Pharmaceuticals
    Full Title: In vitro evaluation of allergic reactions in hemophilia B subjects who have exhibited a systemic allergic response after exposure to BeneFIX (Nonacog Alfa; recombinant Factor IX)
    Medical condition: Hemophilia B
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004768-22 Sponsor Protocol Number: C-05-30 Start Date*: 2006-06-12
    Sponsor Name:ALCON ITALIA
    Full Title: Clinical study of the mast-cell stabilizing effects of the Olopatadine using the Conjunctival Allergen Challeenge model
    Medical condition: subjects with a clinical history of seasonal allergic conjunctivitis, but asymptomatic and free of any topical or systemic medication at baseline
    Disease: Version SOC Term Classification Code Term Level
    6.1 10010744 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004427-37 Sponsor Protocol Number: 5421234 Start Date*: 2019-02-20
    Sponsor Name:Odense Research Centre for Anaphylaxis (ORCA)
    Full Title: Treatment with Omalizumab in food allergic children
    Medical condition: Food Allergy with Anaphylaxis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10064075 Seafood allergy LLT
    20.0 100000004870 10014315 Egg allergy LLT
    20.0 100000004870 10016709 Fish allergy LLT
    20.0 100000004870 10040539 Shellfish allergy LLT
    20.0 100000004870 10001745 Allergy to cow's milk LLT
    20.1 100000004870 10034202 Peanut allergy LLT
    20.0 100000004870 10011240 Cow's milk allergy LLT
    20.1 100000004870 10054957 Allergy to grains LLT
    20.1 100000004870 10054959 Allergy to nuts LLT
    20.0 100000004870 10076438 Milk protein allergy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000276-10 Sponsor Protocol Number: FAST2015 Start Date*: 2015-07-02
    Sponsor Name:FAST Consortium under EU 7. FWP
    Full Title: FAST – Food Allergy Specific ImmunoTherapy A multinational phase IIb study to investigate the efficacy and safety of subcutaneous immunotherapy with a modified fish- parvalbumin given in single ri...
    Medical condition: Food allergy to fish
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IS (Completed) DK (Completed) GR (Ongoing) NL (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003627-30 Sponsor Protocol Number: 20170367744 Start Date*: 2018-06-27
    Sponsor Name:Odense Research Center for Anaphylaxis (ORCA)
    Full Title: Protection from food induced anaphylaxis by reducing serum level of specific IgE
    Medical condition: Food Allergy with Anaphylaxis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10014315 Egg allergy LLT
    20.0 100000004870 10016709 Fish allergy LLT
    20.0 100000004870 10040539 Shellfish allergy LLT
    20.0 100000004870 10001745 Allergy to cow's milk LLT
    20.1 100000004870 10034202 Peanut allergy LLT
    20.0 100000004870 10027024 Meat allergy LLT
    20.0 100000004870 10011240 Cow's milk allergy LLT
    20.1 100000004870 10054957 Allergy to grains LLT
    20.1 100000004870 10054959 Allergy to nuts LLT
    20.0 100000004870 10064075 Seafood allergy LLT
    20.0 100000004870 10076438 Milk protein allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-001339-33 Sponsor Protocol Number: SCITVITD3 Start Date*: 2018-07-05
    Sponsor Name:Academisch medisch centrum Amsterdam
    Full Title: A randomized, double-blind, placebo-controlled, study to determine the added value of vitamin D3 to treatment with subcutaneous immunotherapy in patients with moderate to severe allergic rhinitis/ ...
    Medical condition: subcutaneous immunotherapy in allergic rhinitis (AR) patients with allergies to birchpollen
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005615-21 Sponsor Protocol Number: 205.341 Start Date*: 2006-07-13
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Crossover Efficacy and Safety Evaluation of 8-Week Treatment Periods of Two Doses [5 µg (2 actuations of 2.5 µg) and µg (2 actuations of 5 µg)] of Ti...
    Medical condition: Patients with severe persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003555 Asthma bronchial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-007659-15 Sponsor Protocol Number: NC-07-03 Start Date*: 2008-04-22
    Sponsor Name:Lumavita AG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Investigate the Efficacy, Safety, and Tolerability of 3 doses of SPK 0602 (pentamycin) Vaginal Tablets vs Placebo (veh...
    Medical condition: Symptomatic Vaginitis due to Bacterial Vaginosis, Candidiasis or Trichomoniasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062167 Vaginitis bacterial PT
    9.1 10046950 Vaginitis LLT
    9.1 10046958 Vaginitis trichomonal LLT
    9.1 10048238 Yeast vaginitis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed) DE (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001413-14 Sponsor Protocol Number: 205.416 Start Date*: 2008-08-20
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 ...
    Medical condition: Patients with severe persistent asthma who are still symptomatic despite being treated with high-dose inhaled corticosteroids and long-acting beta2-agonists. Additional asthma treatments are allowe...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049106 Asthma chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001414-25 Sponsor Protocol Number: 205.417 Start Date*: 2008-08-20
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 ...
    Medical condition: Patients with severe persistent asthma who are still symptomatic despite being treated with high-dose inhaled corticosteroids and long-acting beta2-agonists. Additional asthma treatments are allowe...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049106 Asthma chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 10:42:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA